Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07142902

Gastroduodenal Full Thickness Resection Device Registry - gdFTRD® Registry

Endoscopic full-thickness resection (EFTR) is a therapeutic option for the treatment of challenging lesions such as subepithelial tumors (SETs) and epithelial neoplasia extending deeper than the mucosa or associated with significant fibrosis. EFTR may offer a less invasive treatment alternative relative to surgical approaches in selected patients.

The gastroduodenal FTRD System (gdFTRD System) is an instrument for endoscopic full-thickness resection or deep partial wall resection and diagnostic tissue acquisition through removal of suitable lesions in the stomach and duodenum.

The prospectively generated data of the gdFTRD registry shall be used to evaluate the application of the gdFTRD in clinical routine, to verify the acceptability of already known risks and to identify unknown risks and complications.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitätsklinikum Freiburg - Klinik für Innere Medizin II, Freiburg im Breisgau, Germany

Loading trial locations.

About this study

The gdFTRD registry is a registry on cases completed with the gdFTRD System. The gdFTRD System is used for full-thickness resection but the procedure is not part of the study. Only data processing is conducted within the study. For data processing, an EDC system is used.

There are no patient reported outcomes, only physician-entered data on baseline, intervention/procedure, complications/adverse events and follow-up visits.

Automatic plausibility checks have been programmed for quality assurance. Furthermore, warnings and hints will be given on predefined entries not allowed or to double-check values out of normal ranges. No source data verification is planned but data management will check the entries for completeness.

No coding according to MEDRA or similar systems is planned. As the procedure is not part of the study, every participating site must operate according to their own SOPs. The sponsor and CRO have SOPs in place for conducting a study. Furthermore, data protection requirements and all applicable regulations are followed.

The sample size was calculated based results of peer-reviewed publications on the gdFTRD System. As only continuous and categorial variables will be assessed, no separate statistical analysis plan is planned. In case the collected data allows for exploratory post hoc subgroup analysis further tests can be done according to the descriptions in the protocol. Missing data will not be included in the analysis and shall not be imputed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients of legal age in whom the gdFTRD was used for treatment in the upper GI tract (stomach and duodenum) independently from the registry and
  • who gave informed consent to data processing

Exclusion criteria

  • Patients aged under 18 years
  • Patients in whom the colonic FTRD, diagnostic FTRD or non-device assisted EFTR was used for treatment
  • Patients who did not give informed consent to data processing

Treatment and study plan

Data processing only, treatment is not part of the registry

Other

Treatment with the gdFTRD is part of the clinical routine, the registry only comprises data processing after treatment.

Primary outcomes

  1. Technical success

    Time frame: Directly post-procedure

    Technical success (i.e. target lesion reached and resected; macroscopically complete)

Secondary outcomes

  1. Full thickness resection

    Time frame: Up to 14 days post-procedure

    Full-thickness resection (i.e. histologically confirmed full-thickness resection)

  2. R0 resection

    Time frame: Up to 14 days post-procedure

    R0 resection (i.e. histologically complete lesion resection)

  3. Rate of curative resection (in case of malignant tumors)

    Time frame: Up to 14 days post-procedure

    Rate of curative resection (in case of malignant tumors)

Other outcomes

  1. Incidence of procedure-related adverse events (Safety)

    Time frame: Intra-procedural and directly post-procedure

    Total procedure-related adverse events

  2. Incidence of surgery due to procedure-related adverse events (Safety)

    Time frame: up to 2 weeks post-procedure

    Surgery due to a procedure-related adverse event

  3. Incidence of post-interventional complications (Safety)

    Time frame: up to 2 weeks post-procedure

    Post-interventional complications

  4. Incidence of further procedure-related complications (Safety)

    Time frame: up to 3 years post-procedure

    Other procedure-related complications

Study contacts

Contact information is provided by the study sponsor or research team.

Bettina Stritzke

CONTACT

[email protected]

+49 707196528-174

Marc O. Schurr, Prof. Dr.

CONTACT

[email protected]

+49 707196528-121

Sponsors and collaborators

Lead sponsor

Ovesco Endoscopy AG

Industry

Collaborators

  • novineon CRO GmbH

Registry information

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Aug 27, 2025
Registry last updated
Aug 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.